查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869724

癌症和肿瘤生物标记检测市场规模、份额和趋势分析报告：按癌症类型、生物标记类型、最终用途、地区和细分市场预测（2025-2033 年）

Cancer And Tumor Biomarker-based Assay Market Size, Share & Trends Analysis Report By Cancer Type, By Biomarker Type, By End-use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

癌症和肿瘤生物标记检测市场摘要

2024年全球癌症和肿瘤生物标记检测市场规模估计为109.7亿美元，预计2033年将达到268.1亿美元。

预计2025年至2033年间，该市场将以10.50%的复合年增长率成长，这主要得益于对早期诊断、个人化治疗和精准肿瘤学日益增长的需求。生物标记检测（包括基因组、蛋白质组和代谢组标记）使临床医生能够更早发现癌症、预测疾病进展并更准确地指导治疗方法方案的选择。

次世代定序(NGS)、液态生物检体和多重免疫检测等技术进步提高了检测的灵敏度和通量，同时缩短了周转时间。製药公司正越来越多地与诊断开发商合作，开发标靶治疗的伴随诊断，这进一步推动了市场成长。

分析平台的快速发展正在变革生物标记检测。次世代定序(NGS) 平台具有速度更快、成本更低、灵活性更高的优势，能够进行广泛的基因组检测、肿瘤谱分析以及大规模发现罕见突变。这推动了对检测方法开发和临床应用的需求。同时，液态生物检体（cfDNA、CTC、外泌体）能够以微创的方式进行连续监测、早期检测和追踪治疗抗药性，其便捷性使得检测范围超越了仅依赖组织检体的工作流程。多重 PCR/免疫检测平台和数位病理/影像生物标记进一步实现了少量检体中多种标记物的同步检测，从而提高了诊断准确性并降低了每次有效检测的成本。这些技术共同降低了每次检测的成本，加快了某些工作流程的检测速度，并开启了新的临床应用情境（筛检、微量残存疾病(MRD) 检测和监测）。所有这些都扩大了潜在市场，并吸引了诊断公司和製药合作方的投资。

标靶癌症治疗的兴起，使得药物与生物标记检测紧密结合，从而能够识别合格的患者。随着标靶治疗和免疫疗法核准，这些疗法与特定的基因组、蛋白质组或免疫学特征相关联，製药公司越来越需要检验的伴随诊断试剂盒用于临床试验和监管核准。这推动了对各种适应症的临床检验生物标记检测的需求，也使得与昂贵治疗方法直接相关的检测具有较高的单次检测成本。此外，全面基因组分析的广泛应用以及肿瘤独立性核准的扩展，也促进了多重检测和组合检测的使用，使得资金更多地投入到能够指导多种治疗决策的检测上。这些趋势正在推动诊断公司和药物研发公司之间的併购与合作，加速生物标记检测在全球的商业化应用。

用于治疗选择的生物标记检测，尤其是伴随诊断，面临严格的监管流程，这会影响产品上市时间和商业化成本。监管机构要求进行严格的分析和检验检验，通常要求与治疗药物核准同时或配合提交。此外，新型生物标记和罕见突变也增加了检验研究的检体采集难度。不同的区域法规结构（例如，FDA、EMA 以及不断变化的体外诊断（IVD）法规）也增加了全球推广的复杂性，并可能导致在不同地区重复进行研究和标籤差异。此外，监管机构越来越关注临床效用和真实世界表现，迫使製造商提供上市后证据并实施品质系统（符合体外诊断医疗器材法规 (IVDR) 要求、产生临床证据）。虽然这会增加研发时间和资本支出 (CAPEX)，但最终会提高临床可靠性和支付方的接受度。

目录

第一章 癌症和肿瘤生物标记检测市场：调查方法和范围

2. 癌症和肿瘤生物标记检测市场：执行摘要

  • 市场概述
  • 癌症类型和生物标记类型概览
  • 最终用途简介
  • 竞争格局概览

第三章 癌症和肿瘤生物标记检测市场变数、趋势和范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
  • 市场驱动因素分析
    • 对癌症早期检测的需求日益增长
    • 分子诊断和生物标记发现的进展
    • 癌症发生率上升和个人化医疗的引入
  • 市场限制因素分析
    • 生物标记检测高成本
    • 监管和报销方面的挑战
  • 波特五力分析
  • PESTLE分析

第四章 癌症和肿瘤生物标记检测市场：癌症类型评估和趋势分析

  • 癌症和肿瘤生物标记检测市场：癌症类型差异分析
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 卵巢癌
  • 其他的

第五章 癌症和肿瘤生物标记检测市场：生物标记类型估算和趋势分析

  • 癌症和肿瘤生物标记检测市场：生物标记类型差异分析
  • 遗传/基因生物标誌物
  • 蛋白质生物标记
  • 表观遗传生物标记
  • 其他的

6. 癌症和肿瘤生物标记检测市场：终端用户需求预测和趋势分析

  • 癌症和肿瘤生物标记检测市场：终端用途差异分析
  • 医院和癌症中心
  • 诊断实验室
  • 其他的

7. 癌症和肿瘤生物标记检测市场：区域业务分析

  • 区域市场概况
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
    • 新产品上市
    • 伙伴关係
    • 获得
    • 合作
    • 资金筹措
  • 主要企业市占率分析，2024 年
  • 公司热力图分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd,
    • Thermo Fisher Scientific, Inc.,
    • Illumina, Inc.
    • QIAGEN
    • Guardant Health
    • Exact Sciences Corporation
    • Bio-Rad Laboratories, Inc.
    • Agilent Technologies, Inc.
    • Sysmex Corporation
    • Abbott
    • bioMerieux
    • Myriad Genetics, Inc.
    • Hologic, Inc.
    • Quest Diagnostics Incorporated
Product Code: GVR-4-68040-774-7

Cancer And Tumor Biomarker-based Assay Market Summary

The global cancer and tumor biomarker-based assay market size was estimated at USD 10.97 billion in 2024 and is projected to reach USD 26.81 billion by 2033, growing at a CAGR of 10.50% from 2025 to 2033, driven by the growing demand for early diagnosis, personalized treatment, and precision oncology. Biomarker assays-covering genomic, proteomic, and metabolomic markers-enable clinicians to detect cancers earlier, predict disease progression, and guide therapy selection with higher accuracy.

Advances in technologies such as next-generation sequencing (NGS), liquid biopsy, and multiplex immunoassays are enhancing assay sensitivity and throughput while reducing turnaround times. Pharmaceutical companies increasingly collaborate with diagnostic developers to create companion diagnostics for targeted therapies, further fueling market growth.

Rapid advances in analytic platforms are transforming biomarker testing. Next-generation sequencing (NGS) platforms have become faster, cheaper and more flexible, enabling broad genomic panels, tumor profiling and discovery of rare variants at scale - which drives demand for assay development and clinical adoption. Meanwhile, liquid biopsy (cfDNA, CTCs, exosomes) allows minimally invasive serial monitoring, early detection and therapy resistance tracking; its convenience expands testing volumes beyond tissue-only workflows. Multiplex PCR/immunoassay platforms and digital pathology/imaging biomarkers further enable simultaneous measurement of multiple markers from limited samples, improving diagnostic yield and cost per actionable result. Together these technologies lower per-test costs, shorten time-to-result for certain workflows, and unlock new clinical use cases (screening, MRD, monitoring), all of which expand total addressable market and invite investment from diagnostics firms and pharma co-development partners.

The shift to targeted oncology therapeutics has created a tight coupling between drugs and the biomarker tests that identify eligible patients. As more targeted therapies and immunotherapies receive approvals tied to specific genomic, proteomic or immunologic signatures, pharma companies increasingly require validated companion diagnostics for clinical trials and regulatory approval. This raises demand for clinically validated biomarker assays across indications and supports higher price-per-test economics when tests are linked directly to expensive therapies. Furthermore, broader adoption of comprehensive genomic profiling and tumor-agnostic approvals increases use of multiplex assays and panel testing, concentrating spend on assays that can guide multiple treatment decisions. These dynamics fuel M&A and partnerships between diagnostic companies and drug developers, accelerating commercial rollouts of biomarker assays globally.

Biomarker assays used for treatment selection-especially companion diagnostics-face stringent regulatory pathways that affect time-to-market and commercialization costs. Regulatory agencies require rigorous analytical validation, clinical validation, and often co-submission or alignment with therapeutic approvals; novel biomarkers or rare variants complicate sample accrual for validation studies. Varying regional frameworks (e.g., FDA, EMA, and evolving IVD rules) create complexity for global launches and can force iterative studies or label differences across geographies. Additionally, regulators increasingly scrutinize clinical utility and real-world performance, pushing manufacturers to generate post-market evidence and to adopt quality systems (IVDR compliance, clinical evidence generation), which raises development timelines and CAPEX but ultimately improves clinical confidence and payer acceptance.

Global Cancer And Tumor Biomarker-based Assay Market Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global cancer and tumor biomarker-based assay market based on cancer type, biomarker type, end use, and region:

  • Cancer Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Others
  • Biomarker Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Genetic / Genomic biomarkers
  • Protein biomarkers
  • Epigenetic biomarkers
  • Others
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospitals and Cancer Centers
  • Diagnostic Laboratories
  • Others
  • Regional Outlook (USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Cancer and Tumor Biomarker-based Assay Market: Methodology and Scope

  • 1.1. Market Segmentation and Scope
    • 1.1.1. Segment Definitions
      • 1.1.1.1. Cancer Type Segment
      • 1.1.1.2. Biomarker Type Segment
      • 1.1.1.3. End Use Segment
  • 1.2. Regional Scope
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Objectives
    • 1.4.1. Objective - 1
    • 1.4.2. Objective - 2
    • 1.4.3. Objective - 3
  • 1.5. Research Methodology
  • 1.6. Information Procurement
    • 1.6.1. Purchased Database
    • 1.6.2. GVR's Internal Database
    • 1.6.3. Secondary Sources
    • 1.6.4. Primary Research
  • 1.7. Information or Data Analysis
    • 1.7.1. Data Analysis Models
  • 1.8. Market Formulation & Validation
  • 1.9. Model Details
    • 1.9.1. Commodity Flow Analysis
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations

Chapter 2. Cancer and Tumor Biomarker-based Assay Market: Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Cancer Type and Biomarker Type Snapshot
  • 2.3. End Use Snapshot
  • 2.4. Competitive Landscape Snapshot

Chapter 3. Cancer and Tumor Biomarker-based Assay Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Dynamics
  • 3.4. Market Drivers Analysis
    • 3.4.1. Growing demand for early cancer detection
    • 3.4.2. Advancements in molecular diagnostics and biomarker discovery
    • 3.4.3. Rising cancer prevalence and personalized medicine adoption
  • 3.5. Market Restraint Analysis
    • 3.5.1. High cost of biomarker assays
    • 3.5.2. Regulatory and reimbursement challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. Cancer and Tumor Biomarker-based Assay Market: Cancer Type Estimates & Trend Analysis

  • 4.1. Cancer and Tumor Biomarker-based Assay Market: Cancer Type Movement Analysis
  • 4.2. Breast Cancer
    • 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.3. Lung Cancer
    • 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4. Colorectal Cancer
    • 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Prostate Cancer
    • 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Ovarian Cancer
    • 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Cancer and Tumor Biomarker-based Assay Market: Biomarker Type Estimates & Trend Analysis

  • 5.1. Cancer and Tumor Biomarker-based Assay Market: Biomarker Type Movement Analysis
  • 5.2. Genetic / Genomic biomarkers
    • 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3. Protein biomarkers
    • 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4. Epigenetic biomarkers
    • 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Others
    • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Cancer and Tumor Biomarker-based Assay Market: End Use Estimates & Trend Analysis

  • 6.1. Cancer and Tumor Biomarker-based Assay Market: End Use Movement Analysis
  • 6.2. Hospitals and Cancer Centers
    • 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.4. Others
    • 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Cancer and Tumor Biomarker-based Assay Market: Regional Business Analysis

  • 7.1. Regional Market Snapshot
  • 7.2. North America
    • 7.2.1. North America Cancer and Tumor Biomarker-based Assay Market Estimates And Forecast, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.2.2. Key Country Dynamics
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. Reimbursement Scenario
      • 7.2.2.5. Competitive Scenario
    • 7.2.3. Canada
      • 7.2.3.1. Canada Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.3.2. Key Country Dynamics
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Reimbursement Scenario
      • 7.2.3.5. Competitive Scenario
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.2.4.2. Key Country Dynamics
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Reimbursement Scenario
      • 7.2.4.5. Competitive Scenario
  • 7.3. Europe
    • 7.3.1. Europe Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.2.2. Key Country Dynamics
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Reimbursement Scenario
      • 7.3.2.5. Competitive Scenario
    • 7.3.3. Germany
      • 7.3.3.1. Germany Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.3.2. Key Country Dynamics
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. Reimbursement Scenario
      • 7.3.3.5. Competitive Scenario
    • 7.3.4. Spain
      • 7.3.4.1. Spain Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.4.2. Key Country Dynamics
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. Reimbursement Scenario
      • 7.3.4.5. Competitive Scenario
    • 7.3.5. France
      • 7.3.5.1. France Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.5.2. Key Country Dynamics
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Reimbursement Scenario
      • 7.3.5.5. Competitive Scenario
    • 7.3.6. Italy
      • 7.3.6.1. Italy Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.6.2. Key Country Dynamics
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Reimbursement Scenario
      • 7.3.6.5. Competitive Scenario
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.7.2. Key Country Dynamics
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Reimbursement Scenario
      • 7.3.7.5. Competitive Scenario
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.8.2. Key Country Dynamics
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Reimbursement Scenario
      • 7.3.8.5. Competitive Scenario
    • 7.3.9. Norway
      • 7.3.9.1. Norway Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.3.9.2. Key Country Dynamics
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Reimbursement Scenario
      • 7.3.9.5. Competitive Scenario
  • 7.4. Asia Pacific
    • 7.4.1. Asia-Pacific Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.2.2. Key Country Dynamics
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Scenario
      • 7.4.2.5. Competitive Scenario
    • 7.4.3. China
      • 7.4.3.1. China Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.3.2. Key Country Dynamics
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Scenario
      • 7.4.3.5. Competitive Scenario
    • 7.4.4. India
      • 7.4.4.1. India Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.4.2. Key Country Dynamics
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Scenario
      • 7.4.4.5. Competitive Scenario
    • 7.4.5. South Korea
      • 7.4.5.1. South Korea Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.5.2. Key Country Dynamics
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. Reimbursement Scenario
      • 7.4.5.5. Competitive Scenario
    • 7.4.6. Thailand
      • 7.4.6.1. Thailand Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.6.2. Key Country Dynamics
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Reimbursement Scenario
      • 7.4.6.5. Competitive Scenario
    • 7.4.7. Australia
      • 7.4.7.1. Australia Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.4.7.2. Key Country Dynamics
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Reimbursement Scenario
      • 7.4.7.5. Competitive Scenario
  • 7.5. Latin America
    • 7.5.1. Latin America Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.5.2.2. Key Country Dynamics
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Scenario
      • 7.5.2.5. Competitive Scenario
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.5.3.2. Key Country Dynamics
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Scenario
      • 7.5.3.5. Competitive Scenario
  • 7.6. MEA
    • 7.6.1. MEA Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.2.2. Key Country Dynamics
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Scenario
      • 7.6.2.5. Competitive Scenario
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.3.2. Key Country Dynamics
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Scenario
      • 7.6.3.5. Competitive Scenario
    • 7.6.4. UAE
      • 7.6.4.1. UAE Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.4.2. Key Country Dynamics
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Scenario
      • 7.6.4.5. Competitive Scenario
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Cancer and Tumor Biomarker-based Assay Market, 2021 - 2033 (USD Million)
      • 7.6.5.2. Key Country Dynamics
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Scenario
      • 7.6.5.5. Competitive Scenario

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
    • 8.2.1. New product launch
    • 8.2.2. Partnerships
    • 8.2.3. Acquisition
    • 8.2.4. Collaboration
    • 8.2.5. Funding
  • 8.3. Key Company Market Share Analysis, 2024
  • 8.4. Company Heat Map Analysis
  • 8.5. Company Profiles
    • 8.5.1. F. Hoffmann-La Roche Ltd,
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Thermo Fisher Scientific, Inc.,
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Illumina, Inc.
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. QIAGEN
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Guardant Health
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Exact Sciences Corporation
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Bio-Rad Laboratories, Inc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Agilent Technologies, Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Sysmex Corporation
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Abbott
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. bioMerieux
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Myriad Genetics, Inc.
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Hologic, Inc.
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives
    • 8.5.14. Quest Diagnostics Incorporated
      • 8.5.14.1. Company Overview
      • 8.5.14.2. Financial Performance
      • 8.5.14.3. Product Benchmarking
      • 8.5.14.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviation
  • Table 3 Global Cancer and Tumor Biomarker-based Assay Market, By Region, 2021 - 2033 (USD Million)
  • Table 4 Global Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 5 Global Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 6 Global Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 7 North America Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 8 North America Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 9 North America Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 10 North America Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 11 U.S. Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 12 U.S. Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 13 U.S. Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 14 Canada Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 15 Canada Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 16 Canada Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 17 Mexico Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 18 Mexico Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 19 Mexico Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 20 Europe Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 21 Europe Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 22 Europe Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 23 Europe Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 24 UK Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 25 UK Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 26 UK Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 27 Germany Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 28 Germany Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 29 Germany Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 30 France Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 31 France Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 32 France Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 33 Italy Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 34 Italy Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 35 Italy Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 36 Spain Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 37 Spain Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 38 Spain Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 39 Sweden Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 40 Sweden Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 41 Sweden Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 42 Norway Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 43 Norway Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 44 Norway Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 45 Denmark Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 46 Denmark Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 47 Denmark Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 , (USD Million)
  • Table 49 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 52 Japan Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 53 Japan Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 54 Japan Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 55 China Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 56 China Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 57 China Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 58 India Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 59 India Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 60 India Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 61 Australia Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 62 Australia Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 63 Australia Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 64 Thailand Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 65 Thailand Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 66 Thailand Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 67 South Korea Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 68 South Korea Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 69 South Korea Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 70 Latin America Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 71 Latin America Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 72 Latin America Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 73 Latin America Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 74 Brazil Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 75 Brazil Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 76 Brazil Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 77 Argentina Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 78 Argentina Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 79 Argentina Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 80 MEA Cancer and Tumor Biomarker-based Assay Market, By Country, 2021 - 2033 (USD Million)
  • Table 81 MEA Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 82 MEA Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 83 MEA Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 84 South Africa Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 85 South Africa Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 86 South Africa Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 90 UAE Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 91 UAE Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 92 UAE Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)
  • Table 93 Kuwait Cancer and Tumor Biomarker-based Assay Market, By Cancer Type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait Cancer and Tumor Biomarker-based Assay Market, By Biomarker Type, 2021 - 2033 (USD Million)
  • Table 95 Kuwait Cancer and Tumor Biomarker-based Assay Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Market summary
  • Fig. 4 Market segmentation & scope
  • Fig. 5 Market size and growth prospects
  • Fig. 6 Global cancer and tumor biomarker-based assay market- Key market driver analysis
  • Fig. 7 Global cancer and tumor biomarker-based assay market - Key market restraint analysis
  • Fig. 8 Penetration & growth prospect mapping
  • Fig. 9 Global cancer and tumor biomarker-based assay market - Porter's analysis
  • Fig. 10 Global cancer and tumor biomarker-based assay market - PESTEL analysis
  • Fig. 11 Global cancer and tumor biomarker-based assay market cancer Type outlook key takeaways
  • Fig. 12 Global cancer and tumor biomarker-based assay market: cancer Type movement analysis
  • Fig. 13 Breast cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 14 Lung cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 15 Colorectal cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 16 Prostate cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 17 Ovarian cancer market estimates, 2021 - 2033 (USD Million)
  • Fig. 18 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 19 Global cancer and tumor biomarker-based assay market biomarker type outlook key takeaways
  • Fig. 20 Global cancer and tumor biomarker-based assay market: biomarker type movement analysis
  • Fig. 21 Genetic / Genomic biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 22 Protein biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 23 Epigenetic biomarkers market estimates, 2021 - 2033 (USD Million)
  • Fig. 24 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 25 Global cancer and tumor biomarker-based assay market end use outlook key takeaways
  • Fig. 26 Global cancer and tumor biomarker-based assay market: end use movement analysis
  • Fig. 27 Hospitals and cancer centers market estimates, 2021 - 2033 (USD Million)
  • Fig. 28 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
  • Fig. 29 Others market estimates, 2021 - 2033 (USD Million)
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 Global cancer and Tumor Biomarker-based Assay market: Regional movement analysis
  • Fig. 32 North America cancer and Tumor Biomarker-based Assay market, 2021 - 2033 (USD Million)
  • Fig. 33 U.S. cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 35 Mexico cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 36 Europe cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 37 UK cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 38 Germany cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 39 France cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 40 Spain cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 41 Italy cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 42 Denmark cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 43 Sweden cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 44 Norway cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 45 Asia Pacific cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 46 Japan cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 47 China cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 48 India cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 49 South Korea cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 50 Australia cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 51 Thailand cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 52 Latin America cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 53 Brazil cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 54 Argentina cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 55 MEA cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 56 South Africa cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 57 Saudi Arabia cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 58 UAE cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 59 Kuwait cancer and tumor biomarker-based assay market, 2021 - 2033 (USD Million)
  • Fig. 60 Strategy framework